Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
Type:
Grant
Filed:
February 20, 2019
Date of Patent:
March 3, 2020
Assignee:
Nevakar Inc.
Inventors:
Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
Type:
Grant
Filed:
February 20, 2019
Date of Patent:
February 25, 2020
Assignee:
Nevakar Inc.
Inventors:
Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev
Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
April 9, 2019
Assignee:
Nevakar Inc.
Inventors:
Navneet Puri, Prem Sagar Akasapu, Irfan A. Mohammed, Kumaresh Soppimath, Iouri V. Ilitchev, Tao Zhang
Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-nor epinephrine and exhibit less than 5% degradation of total norepinephrine.
Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
August 21, 2018
Assignee:
NEVAKAR INC.
Inventors:
Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri